

**AWMSG ADVICE SUPERSEDED BY  
NICE GUIDANCE (TA427)  
NICE GUIDANCE ISSUED JANUARY 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation**

**Advice No: 1315 – July 2015**

**Pomalidomide (Imnovid<sup>®</sup>▼)  
1 mg, 2 mg, 3 mg and 4 mg hard capsules**

**Resubmission by Celgene Ltd**

**Recommendation of AWMSG**

**Pomalidomide (Imnovid<sup>®</sup>▼) is recommended as an option for use within NHS Wales in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.**

**This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.**

**Additional note(s):**

- AWMSG acknowledged that the AWMSG criteria for appraising life-extending, end-of-life medicines did apply to pomalidomide (Imnovid<sup>®</sup>▼) for the indication under consideration.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2590), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1315:  
Pomalidomide (Imnovid<sup>®</sup>▼) 1 mg, 2 mg, 3 mg and 4 mg hard capsules. July 2015.

